Assist. Prof. Dr. Hasti Kamali Sarvestani | Medical Mycology | Editorial Board Member
Assistant Professor | Tehran University of Medical Sciences | Iran
Assist. Prof. Dr. Hasti Kamali Sarvestani is a recognized academic and clinical researcher whose work is firmly centered on Medical Mycology, with a strong emphasis on translational research that bridges laboratory diagnostics and patient care. Her scholarly contributions have significantly advanced Medical Mycology through in-depth investigations of fungal pathogens affecting immunocompromised and hospitalized populations, with particular attention to opportunistic infections, antifungal resistance, and molecular identification strategies. Medical Mycology remains the unifying theme across her research portfolio, reflected in her sustained focus on clinically relevant fungi, emerging mycotic diseases, and improved diagnostic accuracy in Medical Mycology practice. Assist. Prof. Dr. Hasti Kamali Sarvestani has authored and co-authored numerous peer-reviewed articles in well-regarded international journals, with her publications collectively demonstrating a strong citation impact within the Medical Mycology community. Her research output spans epidemiological studies, molecular and phenotypic characterization of fungal species, antifungal susceptibility profiling, and the clinical implications of fungal co-infections, reinforcing the applied value of Medical Mycology in modern healthcare systems. Through collaborative research with multidisciplinary teams, she has contributed to strengthening Medical Mycology networks that integrate clinicians, microbiologists, and laboratory scientists. A key strength of her work in Medical Mycology lies in the integration of molecular methods with conventional diagnostics, supporting earlier detection and more targeted antifungal therapy. Her studies have informed clinical decision-making, infection control strategies, and laboratory protocols, thereby enhancing patient outcomes and public health awareness related to fungal diseases. Beyond publications, her active engagement in collaborative research initiatives highlights her role in advancing Medical Mycology at both national and international levels, fostering knowledge exchange and capacity building. The societal impact of Assist. Prof. Dr. Hasti Kamali Sarvestani’s work is evident in its contribution to improved understanding of fungal infections, optimization of diagnostic workflows, and support for evidence-based antifungal management. Her sustained commitment to Medical Mycology underscores her standing as a reliable and influential contributor to this specialized field. Google Scholar profile of 379 Citations, 11 h-index, 14 i10-index.
Profile: Google Scholar
Featured Publications
1. Abdollahi, A., Kamali Sarvestani, H., Rafat, Z., Ghaderkhani, S., & colleagues. (2021). The association between the level of serum 25(OH) vitamin D, obesity, and underlying diseases with the risk of developing COVID-19 infection: A case–control study. Journal of Medical Virology, 93(4), 2359–2364.
2. Sarwestani, H. K., Ghazvini, R. D., Hashemi, S. J., Rezaie, S., Shoar, M. G., & colleagues. (2019). Investigation of etiologic agents and clinical presentations of otomycosis at a tertiary referral center in Tehran, Iran. Iranian Journal of Public Health, 48(2), 331–338.
3. Ardi, P., Daie-Ghazvini, R., Hashemi, S. J., Salehi, M. R., Bakhshi, H., Rafat, Z., & colleagues. (2020). Study on invasive aspergillosis using galactomannan enzyme immunoassay and determining antifungal drug susceptibility among hospitalized patients with hematologic malignancies. Microbial Pathogenesis, 147, 104382.
4. Sarwestani, Z. K., Hashemi, S. J., Rezaie, S., Shoar, M. G., Mahmoudi, S., Elahi, M., & colleagues. (2018). Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients. Journal de Mycologie Médicale, 28(2), 279–284.
5. Rafat, Z., Ramandi, A., Khaki, P. A., Ansari, S., Ghaderkhani, S., Haidar, H., & colleagues. (2022). Fungal and bacterial co-infections of the respiratory tract among patients with COVID-19 hospitalized in intensive care units. Gene Reports, 27, 101588.